

Table 1: Demographic, chronic diagnoses, and chronic medications

		2019 A	2019 B	2019 C	2020 A Pre- lockdown	2020 B Lockdown	2020 C Post- lockdown	p-value for 6 periods	p-value for comparison of 2019 vs
<b>Age, years Mean ±SD</b>		6.75 ±4.38	6.71 ±4.47	6.08 ±4.14	7.38 ±4.15	7.96 ±4.75	8.22 ±5.23	0.060	0.002
<b>Male, n (%)</b>		71 (58.2%)	56 (63.6%)	39 (66.1%)	65 (52.8%)	27 (54.0%)	40 (64.5%)	0.384	0.207
<b>Bedouins, n (%)</b>		99 (79.8%)	54 (60.7%)	37 (61.7%)	79 (63.2%)	40 (78.4%)	41 (65.1%)	0.002	0.032
<b>Chronic (%) diagnoses, n</b>	Atopy	2 (1.6%)	1 (1.1%)	1 (1.7%)	0 (0.0%)	1 (2.0%)	1 (1.6%)	0.690	0.614
	Premature birth	1 (0.8%)	1 (1.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0.501	0.612
	Pulmonary HTN,	3 (2.4%)	0 (0.0%)	1 (1.7%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	0.378	0.291
	OSA, Upper airway obstruction	1 (0.8%)	2 (2.2%)	2 (3.3%)	3 (2.4%)	0 (0.0%)	0 (0.0%)	0.729	0.326
	BPD	2 (1.6%)	0 (0.0%)	0 (0.0%)	1 (0.8%)	0 (0.0%)	0 (0.0%)	1.000	0.454
	Chronic respiratory diagnosis	6 (4.8%)	289 (2.2%)	2 (3.3%)	5 (4.0%)	0 (0.0%)	0 (0.0%)	0.293	0.119
	Chronic non- respiratory diagnosis	15 (12.1%)	10 (11.2%)	9 (15.0%)	13 (10.4%)	5 (9.8%)	6 (9.5%)	0.390	0.934
	ICS	14 (11.3%)	8 (9.0%)	10 (16.7%)	10 (8.0%)	5 (9.8%)	5 (7.9%)	0.210	0.538
	LABA	1 (0.8%)	1 (1.1%)	2 (3.3%)	3 (2.4%)	3 (5.9%)	3 (4.8%)	0.099	0.327
	SABA	2 (1.6%)	0 (0.0%)	3 (5.0%)	3 (2.4%)	4 (7.8%)	1 (1.6%)	0.277	0.068
	LTRA	4 (3.2%)	4 (4.5%)	2 (3.3%)	3 (2.4%)	2 (3.9%)	1 (1.6%)	0.455	0.921
	Chronic respiratory treatment	16 (12.9%)	11 (12.4%)	11 (18.3%)	11 (8.8%)	7 (3.7%)	6 (9.5%)	0.180	0.539
	Chronic non- respiratory treatment	22 (17.7%)	10 (11.2%)	12 (20.0%)	14 (11.2%)	3 (5.9%)	4 (6.3%)	0.013	0.060
<b>Chronic treatment, n (%)</b>									

HTN- hypertension, OSA- obstructive sleep apnea, BPD- bronchopulmonary dysplasia, ICS- inhaled corticosteroids, SABA- short acting beta agonist, LABA- long acting beta agonist, LTRA- leukotriene receptor antagonist.